NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12)

The summary for the NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12): This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (scholars) leading to research independence in the area of drug abuse and addiction. For this FOA, clinician scientists may include (but are not limited to) physicians, clinical psychologists, epidemiologists, doctoral-level social workers, pharmacists, and behavioral scientists. Scholars are expected to be supported for 3-5 years on consecutive 12-month appointments. Candidates selected for support as scholars must hold a doctorate and commit a minimum of 9 person-months (equivalent to 75% of full-time professional effort) to conducting clinical research and career development activities associated with the proposed program.

Federal Grant Title:	NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-13-163
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	Sep 07, 2015
Original Application Deadline:	Sep 07, 2015
Posted Date:	Mar 28, 2013
Creation Date:	Mar 28, 2013
Archive Date:	Oct 08, 2015
Total Program Funding:
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program. In many cases, it is anticipated that the proposed program will complement other ongoing research training, research education, and career development programs occurring at the applicant institution and that a substantial number of program faculty will have active research projects in which participating scholars may gain relevant experiences consistent with their research interests and goals. Institutions with existing K12 programs must explain what distinguishes this program from the others, how their programs will synergize with one another, if applicable, and make it clear that the pool of faculty, potential scholars, and resources are robust enough to support additional programs. If multiple sites are involved in the institutional career development program, the applicant institution must be one of these sites for the program. The need for and use of multiple sites must be justified.
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...